Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Entyvio Superior to Humira in Ulcerative Colitis

Japan’s Takeda Pharmaceutical presented more data from the company’s Phase IIIb head-to-head VARSITY clinical trial of Entyvio compared to AbbVie’s Humira in ulcerative colitis.

Read More »

Novartis lands assets from inflammation specialist IFM

Novartis agreed to pay $310 million upfront, with the possibility for more later, for some research assets of Boston-based inflammation specialist IFM Therapeutics as the Swiss drugmaker expands the company’s immunology pipeline.

Read More »

Inflammatory bowel disease tied to heart attack risk

People with inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis may be up to 12 times more likely to have a heart attack, a U.S. study suggests.

Read More »

J&J’s Stelara succeeds in chronic bowel disease study

Johnson & Johnson said the company’s blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial.

Read More »

Abivax reports impressive results for experimental oral treatment for ulcerative colitis

Abivax – a biotechnology company harnessing the immune system to develop a functional cure for HIV, as well as treatments for inflammatory/autoimmune diseases and cancer – today announced top-line results from its Phase 2a clinical trial, ABX464-101.

Read More »

Xeljanz Receives EU Marketing Authorization For Moderately To Severely Active Ulcerative Colitis

Pfizer Inc. announced that the European Commission approved Xeljanz (tofacitinib citrate) 10 mg twice daily for at least eight weeks, followed by Xeljanz 5 mg BID or 10 mg BID, for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Read More »

FDA clears Pfizer’s Xeljanz for inflammatory bowel disease

The U.S. FDA approved Pfizer’s blockbuster drug Xeljanz to treat adults with moderate-to-severe active ulcerative colitis.

Read More »

Janssen, Theravance Ink $1 Billion Collaboration

Janssen Pharmaceutical of Johnson & Johnson inked a global collaboration deal with Theravance Biopharma to develop a drug for inflammatory bowel diseases (IBD).

Read More »

Celgene Ends Two Phase III Trials

Celgene is scrapping a late-stage Crohn’s disease drug it acquired in a $710 million deal three years ago following an interim data analysis.

Read More »

Shire buys bowel drug rights from Pfizer

Irish drugmaker Shire Plc said it would buy the rights to an experimental bowel drug from Pfizer Inc to bolster its pipeline of gastrointestinal treatments.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom